bone morphogenetic protein-2
Recombinant proteinexperimental
Clinical trial activity
16 trials · 14 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
6
Phase 3
2
Phase 4
3
Earliest trial started Nov 1, 2003 (NCT00243295)
Timeline
Indications
Approved for
Studied for
- Bone Diseases · Phase 1
- Fractures, Bone · Phase 2/Phase 3
- Malocclusion · Phase 2
- Maxillary Sinus · Phase 3
- Osteoarthritis · Phase 1
- Osteoporosis · Phase 2
- Periodontal Diseases · Phase 4
- Periodontitis · Phase 2
- Radius Fractures · Phase 1
- Retroperitoneal Fibrosis · Phase 4
- Spinal Fusion · Phase 4
- Spinal Injuries · Phase 4
Mechanism of action
Bone morphogenetic protein receptor type-1A agonist
- Activin receptor type-2BAGONIST
Activin receptor type-2B agonist
Bone morphogenetic protein receptor type-2 agonist
Bone morphogenetic protein receptor type-1B agonist
- Activin receptor type-2AAGONIST
Activin receptor type-2A agonist
- Activin receptor type-1AGONIST
Activin receptor type-1 agonist
BMP2K agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109171 ↗
Also known as
- bmp-2
- bone morphogenetic protein 2
- bone morphogenetic protein-2
- dfdba
- dibotermin alfa
- dibotermin alfa
- dibotermin alfa
- recombinant human bone morphogenetic protein-2
- recombinant human bone morphogenetic protein-2
- recombinant human bone morphogenetic protein-2
- rhbmp-2
- rhbmp-2 protein, recombinant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04764110 | N/A | Mar 17, 2021 | University of Memphis, ZyCal Bioceuticals |
| NCT04372420 | N/A | Dec 5, 2017 | SVS Institute of Dental Sciences |
| NCT04368650 | Phase 2 | Dec 5, 2017 | SVS Institute of Dental Sciences |
| NCT03527966 | Phase 4 | Jul 3, 2017 | Virtua Health, Inc. |
| NCT02924571 | Phase 4 | Dec 1, 2016 | New York University |
| NCT03396900 | Phase 2 | Jul 1, 2016 | SVS Institute of Dental Sciences |
| NCT03009097 | Phase 4 | Apr 1, 2013 | Kamineni Institute of Dental Sciences |
| NCT01725698 | Phase 1 | Nov 1, 2012 | University of Indonesia |
| NCT01634308 | Phase 3 | Jun 1, 2010 | Bio-alpha Co. LTD., Daewoong Pharmaceutical Co. LTD. |
| NCT00752557 | Phase 2 | Dec 1, 2008 | Pfizer |
| NCT00384852 | Phase 2 | Jan 1, 2007 | Pfizer, Wyeth |
| NCT00384358 | Phase 2 | Dec 1, 2006 | Pfizer |
| NCT00387686 | Phase 2/Phase 3 (Phase 3) | Nov 1, 2006 | Pfizer |
| NCT00161629 | Phase 1 | Sep 1, 2005 | Pfizer, Wyeth |
| NCT01690260 | Phase 1 | Sep 1, 2004 | Aalborg University, Government of Denmark, Medtronic |
| NCT00243295 | Phase 1 | Nov 1, 2003 | Pfizer, Wyeth |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 6 | 6 | 3 | 2003 |
| SVS Institute of Dental Sciences | Academic/Hospital | 3 | 3 | 2 | 2016 |
| Wyeth | For profit | 3 | 0 | 2 | 2003 |
| Aalborg University | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Bio-alpha Co. LTD. | For profit | 1 | 0 | 1 | 2010 |
| Daewoong Pharmaceutical Co. LTD. | For profit | 1 | 1 | 1 | 2010 |
| Government of Denmark | Government | 1 | 1 | 1 | 2004 |
| Kamineni Institute of Dental Sciences | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Medtronic | For profit | 1 | 0 | 1 | 2004 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Indonesia | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of Memphis | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Virtua Health, Inc. | Academic/Hospital | 1 | 1 | 1 | 2017 |
| ZyCal Bioceuticals | For profit | 1 | 0 | 1 | 2021 |
14 organizations
Page 1 / 1